Citations

Clear

5212 citation(s) found for "Wang, Li-Ju".

Treatment Times and In-Hospital Mortality Among Patients with ST-Elevation Myocardial Infarction Throughout the Waves of the COVID-19 Pandemic: Lessons Learned
Zègre‐Hemsey, Jessica K. , Goyal, Abhinav , Poudel, Ram , Thomas, Kathie , Ali, Murtuza J., Best, Patricia J.M. , Bieniarz, Mark, Fonarow, Gregg C. , French, William J. , Henry, Timothy D. , Hong, Haoyun, Jollis, James G. , Redlener, Michael , Spier, Travis, Stone, Harper, Wahab, Feras, Wang, Lanjing , Jacobs, Alice K. , Granger, Christopher B.

Mayo Clinic

COVID | July 25, 2025 | Volume: 5 | Issue: 8 | Pages: 114

10.3390/covid5080114 Get It

Previous studies about the COVID-19 pandemic on STEMI patient outcomes have conflicting results. It remains unclear if this may be attributed to regional differences and/or differences during COVID-19 wave periods. Using the American Heart Association Get With The Guidelines–Coronary Artery Disease registry data, we evaluated (1) time metrics related to STEMI system goals and (2) regional variation in STEMI incidence and in-hospital mortality during pandemic wave time periods. The study included all patients 18–100 years old admitted with STEMI (n = 72,516) to 1 of 435 American Heart Association Get With The Guidelines–Coronary Artery Disease hospitals (1 October 2019–31 December 2021). Of these, 70.8% were male and 73.0% non-Hispanic White, with a median age of 63 (IQR 18) years. Compared to pre-pandemic time frames, patients with STEMI had a higher risk profile, delayed time to treatment, were treated with fibrinolytic therapy or primary PCI, and were transferred for primary PCI at similar rates, and had higher adjusted in-hospital mortality (during the second wave in the South and Midwest). Preservation of STEMI systems of care resulted in an overall lower in-hospital mortality rate than predicted, although opportunities exist to improve treatment delays. Regional differences in mortality rates require further study.
Real-world outcomes of brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma: a CIBMTR analysis
Ahmed, Nausheen , Kambhampati, Swetha , Hamadani, Mehdi , Hu, Zhen‐Huan , Grover, Natalie S. , Shadman, Mazyar , Locke, Frederick L. , Gerson, James N. , Frank, Matthew J. , Budde, Lihua E. , Wang, Michael , Bye, Matthew , Kharfan‐Dabaja, Mohamed A. , Sauter, Craig S. , Logan, Brent R., Nunes, Ana, Dalton, David , Kloos, Ioana , Xu, Hairong, Pasquini, Marcelo C. , Herrera, Alex F. , Thiruvengadam, Swetha Kambhampati , Grover, Natalie S , Gerson, James , Kim, Soyoung , Kharfan-Dabaja, Mohamed A , Hematti, Peiman , Turtle, Cameron J , Ahmed, Sairah , Moskop, Amy , Nunes, Ana , Dalton, David , Pasquini, Marcelo , Herrera, Alex F , Hamadani, Mehdi , Shadman, Mazyar , Ahmed, Nausheen , Locke, Frederick L , Kim, Soyoung , Hematti, Peiman , Turtle, Cameron J. , Ahmed, Sairah , Moskop, Amy , Lee, Daniel Y.

Mayo Clinic

Blood Advances | July 24, 2025 | Volume: 9 | Issue: 20 | Pages: 5382-5396

10.1182/bloodadvances.2024015014 | PMID 40706035 Get It

Abstract Brexucabtagene autoleucel (brexu-cel) is a chimeric antigen receptor T-cell therapy approved for relapsed/refractory mantle cell lymphoma (R/R MCL). Here, we report real-world effectiveness and safety outcomes of brexu-cel in a prospective study of patients with R/R MCL, including subgroups based on prior treatment with Bruton's tyrosine kinase inhibitor, bendamustine, or autologous hematopoietic cell transplant (auto-HCT) and number of prior therapy lines, using Center for International Blood and Marrow Transplant Research registry data. A total of 476 patients with R/R MCL who received brexu-cel between July 2020 and December 2022 were included in the analysis. With a median follow-up of 13.5 months, the overall response rate was 91% and complete response rate was 82%. One-year overall survival and progression-free survival rates were 76% and 63%, respectively. One-year cumulative incidence of nonrelapse mortality was 8%. Prior auto-HCT was associated with better duration of response within 6 months after infusion (hazard ratio [HR], 0.49; 95% confidence interval [CI], 0.28-0.85) but greater risk of immune effector cell–associated neurotoxicity syndrome (odds ratio [OR], 1.66; 95% CI, 1.06-2.60). Prior bendamustine was associated with increased risk of prolonged thrombocytopenia (OR, 1.90; 95% CI, 1.13-3.21). In patients with 1 to 2 prior therapy lines, relapse or progression was less frequent compared with those with ≥3 prior lines (HR, 0.64; 95% CI, 0.42-1.00). Collectively, our results suggest that real-world outcomes with brexu-cel were consistent with those of the ZUMA-2 trial, regardless of prior therapy type or number of prior therapy lines.
Interobserver variability in the histologic evaluation of serrated epithelial change in inflammatory bowel disease among gastrointestinal pathologists: a comparison of two different definitions
Bahceci, Dorukhan , Pai, Rish K. , Brown, Ian , Misdraji, Joseph , Kumarasinghe, Priyanthi , Kakar, Sanjay , Lauwers, Gregory Y. , Choi, Won‐Tak , Kumarasinghe, Priyanthi M , Wang, Dongliang , Choi, Won-Tak , Kakar, Sanjay , Brown, Ian S

Mayo Clinic

Histopathology | July 24, 2025 | Volume: 87 | Issue: 4 | Pages: 606-617

10.1111/his.15523 | PMID 40703051 Get It

AimsThere are no standardized histologic criteria for diagnosing serrated epithelial change (SEC) in inflammatory bowel disease (IBD), but two commonly used definitions are currently in use. The first definition (DEF1) is a simpler definition but requires endoscopic correlation. It encompasses all endoscopically invisible or non‐targeted serrated lesions without morphologic evidence of dysplasia that do not meet the diagnostic criteria of sessile serrated lesion (SSL) or traditional serrated adenoma (TSA). In contrast, the second definition (DEF2) incorporates more complex morphologic criteria (i.e., disorganized crypt architecture with some crypts no longer perpendicular or extending down to the muscularis mucosae, irregular serration spanning the entire thickness of the mucosa, and goblet cell‐rich epithelium), but does not necessitate endoscopic correlation. The reproducibility of SEC diagnoses using these definitions among gastrointestinal (GI) pathologists has not yet been evaluated.Methods and resultsSeven GI pathologists independently evaluated 38 GI cases, including 21 digitally scanned biopsy slides and 17 previously published images, demonstrating various types of serrated changes and their morphologic mimics. The diagnostic categories included: (1) SEC, (2) hyperplastic polyp (HP), (3) SSL, (4) TSA, (5) hypermucinous dysplasia (HMD), and (6) no serrated change or dysplasia (NSD). All cases were selected by a single pathologist (WTC) who did not participate in the interobserver study. The pathologists initially assessed each case as if it were endoscopically normal and provided a diagnosis using DEF1. Next, they re‐evaluated each case, this time considering it as a nodular or polypoid lesion, and again made a diagnosis using DEF1. The same process was then repeated for each case but using DEF2. A total of 532 diagnoses were made for each definition (7 pathologists × 38 cases × 2 endoscopic appearances). Fleiss' kappa statistics were used to assess the level of agreement among the seven pathologists. The total number of SEC diagnoses using DEF1 (n = 110 of 532) was more than twice that of DEF2 (n = 50 of 532). Also, the number of SEC diagnoses per pathologist was higher using DEF1 (mean: 16, range: 12–18) compared to DEF2 (mean: 7, range: 0–14). Furthermore, the instances where four or more pathologists agreed on the diagnosis of SEC were more frequent with DEF1 (16 of 38 cases) than with DEF2 (1 of 38 cases). The overall agreement in diagnosing SEC (vs. no SEC) using DEF1 was substantial (k = 0.69, P < 0.001), whereas the agreement using DEF2 was only slight (k = 0.18, P < 0.001). Among potential SEC mimics, there was substantial agreement in diagnosing HP (k = 0.69 using DEF1), SSL (k = 0.68), TSA (k = 1.00), HMD (k = 0.79), and NSD (k = 0.61) (P < 0.001).ConclusionsThe diagnosis of SEC using DEF1 is significantly more reproducible than using DEF2. Utilizing DEF1 is also less likely to miss potentially important cases of SEC. Therefore, DEF1 could be adopted to separate SEC from other serrated lesions and morphologic mimics in IBD.
Twice‐daily administration improves the effectiveness of 0.01% atropine for controlling myopia in slowing axial elongation and refractive progression
Xu, Shengsong , Wang, M Y , Qu, Yan , Jiang, Jinyun , Zhao, Wenchen , Zheng, Bingru , Lei, Xingyu, Li, Zhouyue , Hu, Yin , Wang, Mengyi , Zhou, Fengqi, Zheng, Bingru , Yang, Xiao , Qu, Yiwen, Wang, Yanbin , Zhou, Fengqi , Chen, Weiyin, Lei, Xingyu

Mayo Clinic

Ophthalmic and Physiological Optics | July 23, 2025 | Volume: 45 | Issue: 7 | Pages: 1856-1866

10.1111/opo.13558 | PMID 40698880 Get It

Abstract Purpose It remains unclear whether increasing the frequency of administration of 0.01% atropine improves its effectiveness in slowing axial elongation or refractive progression. This study compared twice‐daily 0.01% atropine administration and traditional once‐nightly administration. Methods A hybrid design was adopted incorporating both retrospective and prospective elements, with participants observed for 1 year. The control group (received saline eye drops) and once‐daily 0.01% atropine group (Atropine‐1 group) were derived from two previous trials, while the twice‐daily 0.01% atropine group (Atropine‐2 group) was enrolled prospectively. A total of 163 participants were included in the intention‐to‐treat set, with 51, 70 and 42 participants in the control, Atropine‐1 and Atropine‐2 groups, respectively. The primary outcome was the change in axial length (AL), and the secondary outcome was the change in cycloplegic spherical equivalent refraction (SER). Results Compared with the control group (0.48 ± 0.22 mm), both Atropine‐1 (0.26 ± 0.17 mm) and Atropine‐2 (0.15 ± 0.18 mm) groups showed significantly reduced AL elongation ( p < 0.001). Notably, Atropine‐2 significantly improved slowing of AL elongation compared with Atropine‐1 ( p = 0.008). The result of the secondary outcome (adjusted SER change) was consistent. Atropine‐2 was significantly more effective in slowing SER progression (−0.15 ± 0.37 D) than Atropine‐1 (−0.41 ± 0.50 D) ( p = 0.02). Based on a multivariable model, age was identified as the key covariate to perform subgroup analyses. In the younger subgroup (8–10 years), AL elongation was significantly reduced in the Atropine‐2 group (0.16 ± 0.17 mm) compared with the Atropine‐1 group (0.36 ± 0.22 mm; p = 0.002). In the older subgroup (10–12 years), there was no significant difference in progression. Consistent results were observed in the sensitivity analyses based on the per‐protocol set. Conclusion Twice‐daily administration of 0.01% atropine was more effective than once daily in slowing AL elongation and SER progression in children 8 to 10 years of age. Further investigation with extended follow‐up is warranted to substantiate this finding.
Restoration of SIRT3 Expression in Aged Mice Alleviates UUO‐Induced Renal Fibrosis by Reducing GSK‐3β Hyperacetylation
Lu, Huan , Guo, Zihao , Li, Xing , Tian, Yiqun, Yin, Yisheng , Qin, Zhenliang, Yun, Kun , Wu, Minglong, Zeng, Xiaoyong , Zeng, Xiaoyong , Wang, Jing , Ren, Xiang , Yun, Kun, Chen, Gang

Mayo Clinic

Advanced Science | July 23, 2025 | Volume: 12 | Issue: 39 | Pages: No page available

10.1002/advs.202417248 | PMID 40698425 Get It

Abstract Aging increases the vulnerability of kidneys to injury and impairs their regenerative capacity. SIRT3 expression declines with aging and is associated with multiple age‐related pathologies. The expression profile and functional role of SIRT3 in renal aging remain unclear. Here, SIRT3 expression in aging kidneys is assessed and analyzed for its promoter methylation patterns using methylation‐specific PCR (MSP). It is found that aging exacerbates UUO‐induced renal fibrosis, associated with downregulated SIRT3 expression. Mechanistically, age‐related SIRT3 downregulation is mediated by hypermethylation of its promoter region. SIRT3 knockout exacerbated renal fibrosis in young mice subjected to UUO, whereas SIRT3 overexpression attenuated fibrosis in aged UUO mice. Integration of RNA‐seq and immunoprecipitation‐mass spectrometry (IP‐MS) analyses revealed that SIRT3 deficiency leads to hyperacetylation of GSK3β at lysine 15 (K15). This K15 hyperacetylation inhibited GSK3β activity, consequently stabilizing its substrate β‐catenin. Furthermore, self‐assembled PEG‐PCL‐PEG micelles are designed and synthesized to encapsulate hydrophobic honokiol (HKL). These micelles significantly enhanced the aqueous solubility and oral bioavailability of free HKL, maintained stable blood concentrations, and ultimately improved its anti‐fibrotic efficacy. These findings propose novel therapeutic strategies for managing renal fibrosis in the aging population and provide a foundation for developing new drugs and combination therapies.
Deep learning-driven phonetic profiling of dysarthric speech
Wang, Fenqi , Utianski, Rene L. , Duffy, Joseph R. , Jones, David , Botha, Hugo , Jones, David T.

Mayo Clinic

The Journal of the Acoustical Society of America | July 18, 2025 | Volume: 157 | Issue: 4_Supplement | Pages: A78-A78

10.1121/10.0037460 Get It

Dysarthric speech poses significant challenges for clinical assessment and diagnosis due to wide variability in the nature and severity of speech impairments associated with it. To address this, this study investigates the phonetic variations in different types of dysarthric speech using the deep learning model Phonet. Recordings of the word “Catastrophe” from 54 patients diagnosed with dysarthria were analyzed to extract posterior probabilities of consonants and vowels. The analysis revealed distinct posterior probability patterns for consonants and vowels across three types of dysarthria, indicating disorder-specific articulatory-based speech characteristics. Moreover, within each dysarthric group, variations in posterior probabilities aligned with the severity of rated articulation difficulty, reflecting nuanced intra-disease phonetic differences. These findings demonstrate Phonet’s ability to capture subtle speech variations and link them to both dysarthria type and severity. By quantifying these phonetic alterations, this study offers a novel and robust framework for objectively evaluating articulation difficulties in dysarthric speech. The results emphasize the clinical potential of Phonet as an advanced tool for improving the diagnosis and monitoring of dysarthria, paving the way for innovative applications in speech-based clinical assessments.
Self-Reported Resilience During the COVID-19 Pandemic
Ogungbe, Oluwabunmi , Wang, Tianyou , Meyer, Diane , Stukovsky, Karen Hinckley , Kucharska‐Newton, Anna , Gabriel, Kelley Pettee , Regan, Elizabeth A., Talavera, Gregory, Sims, Mario , Contreras, Jose Gutierrez, Kandula, Namratha R. , Lee, Joyce , Woodruff, Prescott G. , Ortega, Victor E. , Fretts, Amanda M. , Putcha, Nirupama , Hansel, Nadia N. , Oelsner, Elizabeth C. , Oelsner, Elizabeth C , Kucharska-Newton, Anna M , Lee, Joyce S , Balte, Pallavi , Slone, Sarah , Allen, Norrina B. , Buhr, Russell G. , Hirsch, Jana A. , Xanthakis, Vanessa , Isasi, Carmen R. , Daviglus, Martha , Perreira, Krista M. , Contreras, Jose Gutierrez, Howard, Virginia J. , Judd, Suzanne E. , Wenzel, Sally E. , Phipatanakul, Wanda , Post, Wendy S.

Mayo Clinic

JAMA Network Open | July 16, 2025 | Volume: 8 | Issue: 7 | Pages: e2520360

10.1001/jamanetworkopen.2025.20360 | PMID 40668582 Get It

ImportanceIdentifying factors associated with resilience during the COVID-19 pandemic can inform targeted interventions and resource allocation for groups disproportionately affected by systemic inequities.ObjectiveTo examine factors associated with self-reported resilience during the COVID-19 pandemic in racially and ethnically diverse, community-dwelling US adults.Design, Setting, and ParticipantsThis cross-sectional study was conducted as part of the Collaborative Cohort of Cohorts for COVID-19 Research (C4R) study, which assessed the associations of the pandemic with self-reported resilience of participants from 14 established US prospective cohorts since January 2021. This report includes participants who responded to the self-reported resilience question on C4R questionnaires. Data was initially analyzed from October 2023 to May 2024, with updated analyses performed from August 2024 to April 2025.ExposureRace and ethnicity, behavior factors, health conditions, and social determinants of health measurements accessed before and during the COVID-19 pandemic through cohort visits and C4R questionnaires.Main Outcomes and MeasuresSelf-reported resilience was collected via 1 question (from the Brief Resilience Scale) in C4R questionnaires, “I tend to bounce back quickly after hard times.” Participants who answered agree or strongly agree were classified as resilient, and those who reported neutral, disagree, or strongly disagree were classified as not resilient. Modified Poisson regression was performed to estimate prevalence ratios (PRs) and access multivariable-adjusted associations with resilience.ResultsOf 31 045 participants (18 672 [60%] women; 10 746 [34.6%] aged &amp;lt;65 years), 1185 (3.8%) identified as American Indian, 6728 (21.7%) as Black, 293 (0.9%) as East Asian, 6311 (20.3%) as Hispanic, 565 (1.8%) as South Asian, and 15 961 (51.3%) as White; a total of 23 103 participants (74.4%) self-identified as resilient. Compared with White participants, Black and Hispanic participants had higher prevalence of self-reported resilience (adjusted PR [aPR], 1.04; 95% CI, 1.02-1.06; aPR, 1.08; 95% CI, 1.06-1.11; respectively) and American Indian and East Asian participants had lower prevalence (aPR, 0.90; 95% CI, 0.86-0.94; aPR, 0.76; 95% CI, 0.68-0.84; respectively). Higher education, being married or living as married, higher income, and overweight were also associated with higher prevalence of resilience. Being female, having diabetes, and being unemployed were associated with lower prevalence of self-reported resilience. Compared with participants with public insurance only, participants with private insurance had higher prevalence of resilience (aPR, 1.07; 95% CI, 1.03-1.10). COVID-19 vaccination and infection statuses were not significantly associated with resilience. Modification analyses showed important racial and ethnic differences in how factors such as hypertension, marital status, and insurance status were associated with resilience.Conclusions and RelevanceIn this cross-sectional study of 31 045 adults, self-reported resilience varied by race, ethnicity, and sociodemographic factors. These findings highlight the complex interplay of individual and social factors in shaping the perception of resilience.
IRF4 Promotes Immune Evasion and Shapes the Tumor Microenvironment in Follicular Lymphoma
Dasari, Surendra , Wenzl, Kerstin , Nelson, Geoffrey M. , Guzman, Emmanuel Contreras , Wang, Zhiquan , Chartier, Loïc , Yang, Zhi-Zhang , Villasboas, José C. , Olson, Joshua , Mukherjee, Prithviraj , Tang, Xinyi , Gysbers, Brianna J. , Zakrzewski, Johannes L. , King, Rebecca L. , Huet, Sarah , Tesson, Bruno , Nowakowski, Grzegorz S. , Pasqualucci, Laura , Novak, Anne J. , Ansell, Stephen M. , Contreras Guzman, Emmanuel , Bhardwaj, Vaishali , Tang, Xinyi , Gysbers, Brianna J , Zakrzewski, Johannes L , King, Rebecca L , Huet, Sarah , Tesson, Bruno , Maurer, Matthew , Morschhauser, Franck , Nowakowski, Grzegorz S , Adelman, Karen , Singh, Harinder , Pasqualucci, Laura , Shlomchik, Mark , Novak, Anne J , Ansell, Stephen M , Mondello, Patrizia , Villasboas, Jose Caetano , Yang, Zhi-Zhang , Nelson, Geoffrey M , Bhardwaj, Vaishali , Maurer, Matthew J. , Morschhauser, Franck , Mondello, Patrizia , Wang, Zhiquan

Mayo Clinic

Blood Cancer Discovery | July 16, 2025 | Volume: 6 | Issue: 6 | Pages: 623-645

10.1158/2643-3230.bcd-24-0223 | PMID 40668133 Get It

Abstract Twenty percent of patients with follicular lymphoma relapse early with poor outcomes; however, the molecular mechanisms underlying this aggressive behavior are unknown. Using a multiomic approach, we show that patients with follicular lymphoma with elevated IRF4 expression (IRF4hi) have increased transformation risk, dysregulated immune signaling, and a suppressive tumor microenvironment. Loss- and gain-of-function experiments in IRF4hi lymphoma cells, along with chromatin profiling, demonstrate that IRF4 impairs their interaction with T cells by repressing antigen presentation and co-receptor gene modules while promoting the expression of cytokines that antagonize T-follicular helper cell and regulatory T-cell functions. Additionally, IRF4 rewires tumor metabolism and restricts glucose availability to immune cells. Silencing of IRF4 inhibits tumor cell growth and restores immune surveillance mechanisms, thus representing a promising target for therapy. Our data suggest that IRF4hi lymphoma cells co-opt a developmental mechanism used to exit the germinal center response in promoting a more aggressive cancer via engagement of multiple immune-evasive mechanisms. Significance: We show that IRF4 controls immune and metabolic signaling with functional effects on the cross-talk between B and T cells, resulting in a suppressive immune microenvironment when IRF4 is overexpressed in lymphoma. This underscores the importance of IRF4 as a pivotal therapeutic target to restore antitumor immunosurveillance for IRF4-associated lymphomas.
Baseline predictors of poor clinical outcome despite recanalization of distal middle cerebral artery occlusions
Chafai, Imene , Salim, Hamza , Musmar, Basel , Adeeb, Nimer , Yedavalli, Vivek , Tjoumakaris, Stavropoula , Henninger, Nils , Nedelcu, Simona , Sundararajan, Sri Hari , Kühn, Anna Luisa , Khalife, Jane , Tan, Benjamin Yong‐Qiang , Heit, Jeremy J. , Regenhardt, Robert W. , Puri, Ajit S , Dyzmann, Christian , Filipe, João Pedro , Marotta, Thomas R. , Spears, Julian , Biswas, Arundhati , Clarençon, Frédéric , Varela, Ricardo , Baker, Amanda , Altschul, David , Gonzalez, Nestor R. , Möhlenbruch, Markus , Costalat, Vincent , Stracke, Christian Paul , Shaikh, Hamza , Liebeskind, David S. , Alexandre, Andrea , Tancredi, Illario , Faizy, Tobias D. , Kalsoum, Erwah , Patel, Aman B. , Wang, Maud , Lubicz, Boris , Guenego, Adrien , ##, On behalf of the MAD MT Investigators, Tjoumakaris, Stavropoula , Ghozy, Sherief , Scarcia, Luca , Tan, Benjamin Yq , Heit, Jeremy J , Regenhardt, Robert W , Cancelliere, Nicole M , Bernstock, Joshua D , Rouchaud, Aymeric , Fiehler, Jens , Sheth, Sunil A , Essibayi, Muhammed Amir , Colasurdo, Marco , Marnat, Gaultier , Renieri, Leonardo , Filipe, João Pedro , Harker, Pablo , Alexandru Radu, Răzvan , Marotta, Thomas R , Spears, Julian , Ota, Takahiro , Mowla, Ashkan , Jabbour, Pascal , Clarençon, Frédéric , Nguyen, Thanh N , Varela, Ricardo , Altschul, David J , Gonzalez, Nestor R , Möhlenbruch, Markus A , Gory, Benjamin , Stracke, Paul , Hecker, Constantin , Shaikh, Hamza A , Liebeskind, David S. , Pedicelli, Alessandro , Alexandre, Andrea M , Tancredi, Illario , Faizy, Tobias D , Kalsoum, Erwah , Fahed, Robert , Wang, Maud , Mendes Pereira, Vitor , Lubicz, Boris , Dmytriw, Adam A , Guenego, Adrien , Kühn, Anna Luisa , Musmar, Basel , Salim, Hamza , Yedavalli, Vivek S , Henninger, Nils , Nedelcu, Simona , Ghozy, Sherief , Cancelliere, Nicole M , Bernstock, Joshua D. , Rouchaud, Aymeric , Fiehler, Jens , Essibayi, Muhammed Amir , Colasurdo, Marco , Renieri, Leonardo , Harker, Pablo , Radu, Răzvan Alexandru , Mowla, Ashkan , Jabbour, Pascal , Nguyen, Thanh N. , Baker, Amanda, Aziz‐Sultan, Mohammad Ali , Hecker, Constantin , Fahed, Robert , Dmytriw, Adam A. , ##, On behalf of the MAD MT Investigators

Mayo Clinic

Interventional Neuroradiology | July 16, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1177/15910199251342841 | PMID 40665742 Get It

Objective Mechanical thrombectomy (MT) is well-established for the treatment of acute ischemic stroke (AIS) from large vessel occlusion (LVO), with growing data supporting the expansion to distal and medium vessel occlusions (DMVO). Despite successful recanalization in DMVO, certain patients still experience poor long-term clinical outcomes, prompting our study to comprehensively explore pre-MT factors influencing outcome despite excellent recanalization (final modified Thrombolysis in Cerebral Infarction [mTICI] score ≥2c). Methods We retrospectively examined data from patients who consecutively underwent MT for a primary middle cerebral artery (MCA) DMVO across 37 centers in North America, Asia, and Europe. We identified baseline clinical and imaging factors associated with poor clinical outcome (defined as a modified Rankin Scale [mRS] score of 3–6) at 3 months, despite excellent recanalization using a multivariable model. Results Between September 2017 and July 2021, 623 patients achieved mTICI > 2b and they were included in our study. Among them, 198 (32%) experienced a poor clinical outcome (mRS 3–6). Predictors of poor clinical outcome included higher age (OR 1.05 [1.03–1.07], p < 0.001), higher NIHSS at admission (OR 1.12 [1.08–1.15], p < 0.001), higher baseline mRS (OR 1.77 [0.96–3.26], p = 0.067), and diabetes (OR 1.59 [1.01–2.48], p = 0.044). Higher ASPECTS was associated with a decreased risk of poor clinical outcome (OR 0.82 [0.71–0.94], p = 0.006). Conclusion Older age, diabetes, higher baseline mRS, and NIHSS were associated with poor clinical outcome in MCA DMVO despite excellent recanalization. Conversely, a higher ASPECTS decreased the probability of such an outcome.
Fine‐tuning open‐source large language models to improve their performance on radiation oncology tasks: A feasibility study to investigate their potential clinical applications in radiation oncology
Wang, P. , Liu, Zhengliang , Li, Yiwei , Shu, Peng , Li, Xiang , Laughlin, Brady, Toesca, Diego Santos, Vargas, Carlos , Vora, Sujay A., Patel, Samir H. , Liu, Tianming , Wang, Peilong, Laughlin, Brady S. , Toesca, Diego A.S. , Wang, Peilong, Holmes, Jason , Shu, Peng, Zhang, Lian , Li, Quanzheng , Sio, Terence T. , Liu, Wei , Li, Xiang

Mayo Clinic

Medical Physics | July 16, 2025 | Volume: 52 | Issue: 7 | Pages: No page available

10.1002/mp.17985 | PMID 40665561 Get It

Abstract Background The radiation oncology clinical practice involves many steps relying on the dynamic interplay of abundant text data. Large language models have displayed remarkable capabilities in processing complex text information. But their direct applications in specific fields like radiation oncology remain underexplored. Purpose This study aims to investigate whether fine‐tuning LLMs with domain knowledge can improve the performance on Task (1) treatment regimen generation, Task (2) treatment modality selection (photon, proton, electron, or brachytherapy), and Task (3) ICD‐10 code prediction in radiation oncology. Methods Data for 15 724 patient cases were extracted. Cases where patients had a single diagnostic record, and a clearly identifiable primary treatment plan were selected for preprocessing and manual annotation to have 7903 cases of the patient diagnosis, treatment plan, treatment modality, and ICD‐10 code. Each case was used to construct a pair consisting of patient diagnostics details and an answer (treatment regimen, treatment modality, or ICD‐10 code, respectively) for the supervised fine‐tuning of these three tasks. Open source LLaMA2‐7B and Mistral‐7B models were utilized for the fine‐tuning with the Low‐Rank Approximations method. Accuracy and ROUGE‐1 score were reported for the fine‐tuned models and original models. Clinical evaluation was performed on Task (1) by radiation oncologists, while precision, recall, and F‐1 score were evaluated for Task (2) and (3). One‐sided Wilcoxon signed‐rank tests were used to statistically analyze the results. Results Fine‐tuned LLMs outperformed original LLMs across all tasks with p value ≤ 0.001. Clinical evaluation demonstrated that over 60% of the fine‐tuned LLMs‐generated treatment regimens were clinically acceptable. Precision, recall, and F1‐score showed improved performance of fine‐tuned LLMs. Conclusion Fine‐tuned LLMs demonstrated statistically significant improvements over original LLMs upon three clinically important tasks in radiation oncology. This study explored the feasibility of applying fine‐tuned LLMs in radiation oncology, inspiring further development of utilizing LLMs to assist with radiation oncology tasks.